HUBEI GOTO BIOPHARM CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.3 CNY | -7.09% |
|
+14.24% | -11.62% |
| Apr. 26 | Hubei Goto Biopharm Co.,Ltd. Proposes Final Cash Dividend for 2023 | CI |
| Apr. 25 | Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 605M 83.69M | Sales 2023 | 566M 78.4M | Capitalization | 2.65B 367M |
|---|---|---|---|---|---|
| Net income 2022 | 40M 5.54M | Net income 2023 | 23M 3.18M | EV / Sales 2022 | 5.67 x |
| Net Debt 2022 | 317M 43.86M | Net Debt 2023 | 604M 83.57M | EV / Sales 2023 | 5.74 x |
| P/E ratio 2022 |
77.5
x | P/E ratio 2023 |
115
x | Employees | 537 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 38.78% |
More Fundamentals
* Assessed data
More news
| 1 day | -7.09% | ||
| 1 week | +14.24% | ||
| Current month | +14.24% | ||
| 1 month | +19.13% | ||
| 3 months | +47.96% | ||
| 6 months | -16.60% | ||
| Current year | -11.62% |
1 week
17.05
23.80
1 month
13.5723.80
Current year
12.0325.70
1 year
12.0328.78
3 years
12.0372.80
5 years
12.0379.98
10 years
12.0379.98
| Managers | Title | Age | Since |
|---|---|---|---|
Zu Bin Xi
CEO | Chief Executive Officer | 53 | 06-05-14 |
Xiang Dong Liu
DFI | Director of Finance/CFO | 50 | 16-09-30 |
Ming Lei Li
BRD | Director/Board Member | 46 | 08-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cheng Cai Xia
BRD | Director/Board Member | 74 | 18-10-15 |
Jian Yang
BRD | Director/Board Member | 54 | 18-10-15 |
Zu Bin Xi
CEO | Chief Executive Officer | 53 | 06-05-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 20.3 | -7.09% | 12,880,300 |
| 24-05-09 | 21.85 | -4.38% | 18,734,770 |
| 24-05-08 | 22.85 | +20.01% | 16,458,290 |
| 24-05-07 | 19.04 | +4.85% | 9,765,525 |
End-of-day quote Shenzhen S.E., May 09, 2024
More quotes
Hubei Goto Biopharm Co Ltd is a China-based company mainly engaged in the research and development, production and sales of steroidal drug raw materials. The Company's main products are starting materials and intermediates required for the production of steroid drugs. The starting materials refer to the products obtained from the conversion of plant sterols through biological fermentation technology. These products are important raw materials for downstream pharmaceutical intermediates and active pharmaceutical ingredient manufacturers and belong to the upstream products in the steroid drug industry chain. The Company's intermediate products mainly include sex hormone intermediates, progesterone intermediates, corticosteroid intermediates and other products.
Sector
Pharmaceuticals
Calendar
2024-05-17
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -11.62% | 324M | |
| -2.61% | 89.08B | |
| +3.55% | 40.9B | |
| -14.40% | 32.25B | |
| +55.89% | 25.14B | |
| -15.96% | 15.39B | |
| -15.50% | 11.91B | |
| -41.29% | 11.89B | |
| -11.75% | 11.64B | |
| +7.87% | 9.03B |
- Stock Market
- Equities
- 300966 Stock